Clinical genitourinary cancer最新文献

{"title":"Targeting KIT With Antibody-Drug Conjugates in Chromophobe Renal Cell Carcinoma","authors":"Michel Alchoueiry ,&nbsp;Hadi Mansour ,&nbsp;Damir Khabibullin ,&nbsp;Tiegang Han ,&nbsp;Saireudee Chaturantabut ,&nbsp;Wafaa Bzeih ,&nbsp;Yan Tang ,&nbsp;Jessica F. Williams ,&nbsp;Michelle S. Hirsch ,&nbsp;Carmen Priolo ,&nbsp;William R. Sellers ,&nbsp;Elizabeth P. Henske","doi":"10.1016/j.clgc.2025.102359","DOIUrl":"10.1016/j.clgc.2025.102359","url":null,"abstract":"<div><h3>Introduction</h3><div>Chromophobe renal cell carcinoma (ChRCC) is the third most common type of RCC. There are no proven therapies for patients with metastatic ChRCC, with a median survival of 27 months. KIT (CD117) is a membrane-associated tyrosine kinase receptor. Antibody-drug conjugates (ADC) targeting KIT were previously found to be safe and effective in preclinical models of KIT-positive cancers but have not been tested in ChRCC.</div></div><div><h3>Results</h3><div>In The Cancer Genome Atlas, KIT mRNA expression is higher in ChRCC than any other tumor type with the mean expression 12 times higher than matched normal kidney. Of the 15 metastatic ChRCC specimens stained for KIT at our institution, 87% were positive. In single-cell RNA sequencing data, KIT and SCF, the KIT ligand, are co-expressed in ChRCC tumor cells.</div><div>We found that KIT mRNA expression is significantly higher in ChRCC-derived cells compared to clear cell renal cell carcinoma (ccRCC)-derived cells and normal kidney cells. Western blot analysis confirmed KIT expression in 5 ChRCC cell lines. Despite high KIT expression, knockdown of KIT or treatment with KIT targeting tyrosine kinase inhibitors did not decrease ChRCC cell proliferation.</div><div>LOP628, a KIT ADC, decreased the viability of the ChRCC-derived cells by ∼60% with no effect on ccRCC cells.</div></div><div><h3>Conclusion</h3><div>Together, these data demonstrate that KIT is a viable therapeutic target for antibody-drug conjugates in ChRCC, providing a foundation for further investigation into KIT-targeted therapies.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102359"},"PeriodicalIF":2.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144105637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Creatinine-Cystatin C Ratio as a Promising Prognostic Biomarker in Patients With UTUC After Radical Nephroureterectomy","authors":"Lei Zheng ,&nbsp;Jianjun Ye ,&nbsp;Qihao Wang ,&nbsp;Qiyou Wu ,&nbsp;Kai Chen ,&nbsp;Qiang Wei ,&nbsp;Yige Bao","doi":"10.1016/j.clgc.2025.102352","DOIUrl":"10.1016/j.clgc.2025.102352","url":null,"abstract":"<div><h3>Purpose</h3><div>The aim of this study was to determine the impact of the preoperative creatinine-cystatin C ratio (CCR) on the survival prognosis of patients following radical nephrectomy (RNU) for upper tract urothelial carcinoma (UTUC).</div></div><div><h3>Methods</h3><div>The retrospective analysis was conducted on UTUC patients who underwent radical nephrectomy (RNU) at West China Hospital between January 2009 and December 2019. The endpoint of the study was cancer-specific survival (CSS). Kaplan-Meier curves were used to estimate survival, and Cox proportional hazards modelling was used to assess risk. Nomograms were developed to predict CSS at 3 and 5 years of age, and the predictive power was assessed.</div></div><div><h3>Results</h3><div>A critical CCR of 59.61 µmol/mg was demonstrated to affect 504 patients with UTUC who had undergone RNU. A correlation was identified between a lower preoperative CCR and a considerably worse CSS. In patients with UTUC, CCR was identified as an independent risk factor for CSS, particularly in patients with locally advanced UTUC (pT ≥ 3) (HR: 1.84, 95% CI: 1.14, 2.97). Moreover, the CCR-based nomogram exhibited robust predictive capacity, with areas under the curve for the 3- and 5-year CSS reaching 0.823 and 0.793, respectively.</div></div><div><h3>Conclusion</h3><div>Preoperative CCR is an independent predictor of CSS in UTUC patients receiving RNU treatment. As such, it should be viewed as a potentially useful customized tool in therapeutic decision-making.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102352"},"PeriodicalIF":2.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144082778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid Modulation of Circulating Adipokines and Inflammatory Cytokines in Localized Prostate Cancer Following Short-Term Leuprolide Therapy","authors":"Adithya K. Yadalam ,&nbsp;Kiranj Chaudagar ,&nbsp;Hope Mumme ,&nbsp;Manoj Bhasin ,&nbsp;Ganesh R. Talekar ,&nbsp;Edmund K. Waller ,&nbsp;Gregory B. Lesinski ,&nbsp;Sagar A. Patel ,&nbsp;Anant Mandawat","doi":"10.1016/j.clgc.2025.102358","DOIUrl":"10.1016/j.clgc.2025.102358","url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>Cardiovascular disease is a leading cause of death in men with localized prostate cancer, and treatment with androgen deprivation therapy (ADT) is known to exacerbate cardiovascular risk; however, the underlying mechanisms driving ADT-associated cardiotoxicity remain unclear.</div></span></li><li><span>•</span><span><div>In this case series, we observed significant alterations in circulating adipocytokine levels following 6 months of therapy with the gonadotropin-releasing hormone agonist, leuprolide, in 10 men with localized prostate cancer.</div></span></li><li><span>•</span><span><div>The significantly elevated adipocytokine levels following treatment with leuprolide highlight the potential role of ADT-induced systemic inflammation and metabolic dysregulation in the leptin (adipose)-osteopontin (bone) axis in men with localized prostate cancer treated with ADT.</div></span></li></ul></div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102358"},"PeriodicalIF":2.3,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the Impact of Grade Heterogeneity on Survival in Ta and T1 Tumors: A Subgroup Analysis of NMIBC Cohort","authors":"Murat Can Karaburun ,&nbsp;Ezgi Dicle Serbes ,&nbsp;Çağrı Akpınar ,&nbsp;Khaled Obaid ,&nbsp;Cagatay Göğüş ,&nbsp;Saba Kiremitci ,&nbsp;Duygu Enneli ,&nbsp;Sümer Baltacı ,&nbsp;Evren Süer","doi":"10.1016/j.clgc.2025.102357","DOIUrl":"10.1016/j.clgc.2025.102357","url":null,"abstract":"<div><h3>Introduction</h3><div>We aimed to compare the RFS and PFS of Ta-MG, Ta-HG, T1-MG and T1-HG groups with the hypothesis that MG tumors may have a better prognosis than pure HG tumors.</div></div><div><h3>Material and Methods</h3><div>Patients with HG-NMIBC in the first TUR specimen between 2010 and 2020 were screened. The first TUR specimens were re-evaluated by experienced uropathologists and the percentage of LG tumor areas accompanying HG areas was determined for each case. HG tumors with accompanying LG rates ranging from 1% to 95% were evaluated as “Mixed-Grade (MG),” while tumors without any LG component (0%) were evaluated as “pure High-Grade (HG).” Survival analysis was performed using the Kaplan-Meier method. RFS and PFS were compared via the log-rank test.</div></div><div><h3>Results</h3><div>Of the 201 patients included in the study, 25 (12.4%) had Ta-MG, 45 (22.4%) had Ta-HG, 43 (21.4%) had T1-MG and 88 (43.8%) had T1-HG tumors. The median follow-up period of the patients was 36 months. The median number of BCG instillations received by the patients was 12 and a total of 102 patients (50.7%) received a minimum of 12 doses of BCG treatment. Recurrence was observed in 6 (24%), 11 (24.4%), 13 (30.2%) and 30 (34.1%) patients in the Ta-MG, Ta-HG, T1-MG and T1-HG groups, respectively. The 36-month RFS rates were 76% (CI: 59-93), 76% (CI: 63-88), 70% (CI: 56-84) and 66% (CI: 56-76), respectively (Log-Rank; <em>P</em> = .701). Progression was observed in 2 (8%), 3 (6.6%), 2 (4.6%) and 19 (21.6%) patients, respectively. The 36-month PFS rates for groups were 92% (CI: 82-100), 93% (CI: 86-100), 95% (CI: 89-100) and 78% (CI: 70-87), respectively. The T1-HG group was found to have a statistically significantly lower PFS (Log-Rank; <em>P</em> = .016).</div></div><div><h3>Conclusion</h3><div>In BCG-treated NMIBC patients, those with T1-pure-HG tumors have worse PFS compared to those with T1-MG, Ta-HG, and Ta-MG tumors. The presence of pure-HG tumors may hold prognostic importance for NMIBC patients and might be crucial for patient classification and treatment options.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102357"},"PeriodicalIF":2.3,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143928209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes","authors":"Dimitra Rafailia Bakaloudi ,&nbsp;Rafee Talukder ,&nbsp;Thomas Enright ,&nbsp;Jacob B. Leary ,&nbsp;Dimitrios Makrakis ,&nbsp;Leonidas N. Diamantopoulos ,&nbsp;Charbel Hobeika ,&nbsp;Vinay Mathew Thomas ,&nbsp;Umang Swami ,&nbsp;Roubini Zakopoulou ,&nbsp;Aristotelis Bamias ,&nbsp;Jason R. Brown ,&nbsp;David J. Pinato ,&nbsp;Charles Latchford ,&nbsp;Tanya Jindal ,&nbsp;Vadim S. Koshkin ,&nbsp;Jure Murgić ,&nbsp;Marija Miletić ,&nbsp;Ana Frobe ,&nbsp;Jeffrey Johnson ,&nbsp;Petros Grivas","doi":"10.1016/j.clgc.2025.102356","DOIUrl":"10.1016/j.clgc.2025.102356","url":null,"abstract":"<div><h3>Background</h3><div>Immune Checkpoint Inhibitors (ICIs) are used for advanced urothelial carcinoma (aUC) in different settings. Most patients have pure UC (PUC) but about one-third have UC mixed with histology subtypes (HS). We examined outcomes in patients with HS aUC treated with ICI.</div></div><div><h3>Materials and Methods</h3><div>We included patients from 26 centers with PUC and any HS treated with ICI as 1st line (1L) upfront, maintenance avelumab (mAV), and ≥2nd line [2+L] therapy. We calculated overall and progression-free survival (OS, PFS) and observed response rate (ORR) from ICI start.</div></div><div><h3>Results</h3><div>We included 1511 patients; 752 1L, 609 2+L, 150 mAV. 1L: median OS was 15 (95% CI, 12-17) months for patients with PUC (n = 518), 15 (95% CI, 8-23) months for squamous UC (n = 85) (HR = 1.2, [95% CI, 0.8-1.6]), 11 (95% CI, 6-17) months for micropapillary UC (n = 46) (HR = 1.2, [95% 0.8-1.8]), and 21 (95% CI, 12-30) months in patients with UC mixed with ≥2 HS (n = 30), (HR = 0.9, [95% CI, 0.5-1.4]). 2+L: median OS was 9 (95% CI, 8-10) months for patients with PUC (n = 441), 9 (95% CI, 1-12) months for squamous UC (n = 60) (HR = 1.1, (95% CI, 0.8-1.6]), 6 (95% CI, 1-11) months for micropapillary UC (n = 37) (HR = 1.1, [95% 0.7-1.6]), and 7 (95% CI, 4-10) months in patients with UC mixed with ≥2 HS (n = 17), (HR = 1.6, [95% CI, 0.9-3.1]).</div></div><div><h3>Conclusion</h3><div>We found no significant OS difference between PUC and HS in patients with aUC treated with ICI monotherapy. Limitations include retrospective design, small sample size in several subsets, lack of randomization, no central imaging or pathology review, selection and confounding biases. Results are hypothesis-generating and need prospective validation.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102356"},"PeriodicalIF":2.3,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143948108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Clinical Trajectory of Prostate Cancer Patients Harboring Rare Histological Subtypes—A Retrospective Cohort Trial","authors":"Nastasiia Artamonova ,&nbsp;Leon Galleé ,&nbsp;Hannes Neuwirt ,&nbsp;David Heimdörfer ,&nbsp;Michael Ladurner ,&nbsp;Giulia Giannini ,&nbsp;Eberhard Steiner ,&nbsp;Martin Puhr ,&nbsp;Jasmin Bektic ,&nbsp;Wolfgang Horninger ,&nbsp;Isabel Heidegger","doi":"10.1016/j.clgc.2025.102350","DOIUrl":"10.1016/j.clgc.2025.102350","url":null,"abstract":"<div><h3>Background</h3><div>Acinar adenocarcinoma is the most common histological subtype of prostate cancer (PCa). However, 5% of cases present with unconventional histological subtypes (UHs), which have inconsistent clinical characteristics.</div></div><div><h3>Patients and Methods</h3><div>600 patients underwent a radical prostatectomy (RP) at our institution between 2003 and 2023. 50% had UHs, while other 50% age-matched patients (median age 63 years), with pure acinar adenocarcinoma served as comparison group. Collected parameters included age at diagnosis, PSA levels, imaging results, ISUP (International Society of Urological Pathology) Grade Group at biopsy and RP, TNM-stage and biochemical recurrence rates (BCR). Statistical analysis was conducted using SPSS and Excel, applying Mann-Whitney-U, Chi-Square tests, and Cox proportional hazards models to assess associations with recurrence-free survival.</div></div><div><h3>Results</h3><div>All patients with UHs presented mixed histological forms (<em>P</em> &lt; .001). Importantly, UHs were previously identified only in 9% of biopsy specimens (<em>P</em> &lt; .001). Patients with UHs had more aggressive disease reflected by higher ISUP Grade Group (<em>P</em> &lt; .001), higher prevalence of ≥pT3a tumors as well as higher rates of positive resection margins (<em>P</em> &lt; .001) although fewer nerve-sparing procedures were performed (<em>P</em> &lt; .001). Patients with UH had a higher risk of PSA persistence after RP (<em>P</em> = .04) and higher BCR rates (<em>P</em> &lt; .001) after a median follow-up of 54.8 months. Notably, multivariate Cox regression analysis indicated that the presence of UHs is the most significant risk factor for BCR (HR 1.972, 95% CI 1.210-3.312).</div></div><div><h3>Conclusion</h3><div>Patients with UH exhibit more aggressive disease and have an increased risk of disease relapse following curative therapy.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102350"},"PeriodicalIF":2.3,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal Cystoscopic Surveillance Schedule Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma","authors":"Yuhei Koike ,&nbsp;Fumihiko Urabe ,&nbsp;Katsuki Muramoto ,&nbsp;Yuma Goto ,&nbsp;Kosuke Iwatani ,&nbsp;Yu Imai ,&nbsp;Mahito Atsuta ,&nbsp;Keiji Yasue ,&nbsp;Keiichiro Mori ,&nbsp;Hajime Onuma ,&nbsp;Koichi Aikawa ,&nbsp;Kojiro Tashiro ,&nbsp;Jeremy Teoh ,&nbsp;Brendan A. Yanada ,&nbsp;Shunsuke Tsuzuki ,&nbsp;Toshihiro Yamamoto ,&nbsp;Akira Furuta ,&nbsp;Hiroki Yamada ,&nbsp;Jun Miki ,&nbsp;Takahiro Kimura","doi":"10.1016/j.clgc.2025.102354","DOIUrl":"10.1016/j.clgc.2025.102354","url":null,"abstract":"<div><h3>Background</h3><div>Upper tract urothelial carcinoma (UTUC) has shown an increasing incidence, with intravesical recurrence (IVR) being a common postoperative challenge following radical nephroureterectomy. Although current guidelines recommend cystoscopic surveillance based on risk stratification, these recommendations are weak and may not adequately address IVR-specific risk factors or optimal surveillance intervals.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 700 patients who underwent radical nephroureterectomy between 2012 and 2021. Risk factors for IVR were identified using Cox proportional hazards regression models, and optimal cystoscopic intervals were evaluated through hypothetical surveillance models. Gap risk ratios were calculated to assess the risk of delayed IVR detection, stratified by the presence or absence of identified risk factors.</div></div><div><h3>Results</h3><div>The median follow-up duration was 28 months, and IVR occurred in 38.0% of patients. Significant risk factors included a history of bladder cancer, positive voided cytology, and preoperative ureteroscopy. Kaplan–Meier curves revealed significantly worse IVR-free survival in patients with 1 or more risk factors (<em>P</em> &lt; .001). Gap risk ratio analysis supported frequent surveillance during the first postoperative year, with tailored intervals thereafter. For patients without risk factors, surveillance every 3 months during the first year, every 6 months during the second year, and annually thereafter was optimal. For patients with risk factors, surveillance every 3 months during the first year, every 6 months for the next 2 years, and annually thereafter was recommended.</div></div><div><h3>Conclusion</h3><div>Tailored cystoscopic surveillance schedules based on IVR risk factors optimize recurrence detection while minimizing procedural burden. These findings provide an evidence-based framework for individualized surveillance strategies in patients with UTUC following nephroureterectomy.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102354"},"PeriodicalIF":2.3,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical Appraisal of the TRANSLATE Trial","authors":"Caio Suartz","doi":"10.1016/j.clgc.2025.102355","DOIUrl":"10.1016/j.clgc.2025.102355","url":null,"abstract":"","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102355"},"PeriodicalIF":2.3,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143948107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Neoadjuvant Hormonal Therapy for High-Risk Prostate Cancer Undergoing Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Study Using Propensity Score-Matched Analysis in Japan","authors":"Minori Nezasa ,&nbsp;Makoto Kawase ,&nbsp;Satoshi Washino ,&nbsp;Takato Nishino ,&nbsp;Hajime Fukushima ,&nbsp;Kosuke Iwatani ,&nbsp;Tomoaki Miyagawa ,&nbsp;Masaki Shimbo ,&nbsp;Takeshi Yamasaki ,&nbsp;Kojiro Ohba ,&nbsp;Jun Miki ,&nbsp;Kenichiro Ishida ,&nbsp;Takuya Koie","doi":"10.1016/j.clgc.2025.102346","DOIUrl":"10.1016/j.clgc.2025.102346","url":null,"abstract":"<div><h3>Introduction</h3><div>The potential improvement in oncological outcomes of robot-assisted radical prostatectomy (RARP) with neoadjuvant androgen deprivation therapy (ADT) in patients with prostate cancer (PCa) who had high-risk or very-high risk disease (HR/VHR-PCa) remains controversial. This study evaluated the impact of neoadjuvant hormone therapy (NHT) on biochemical recurrence (BCR) following RARP.</div></div><div><h3>Materials and Methods</h3><div>A total of 1,203 patients with HR/VHR-PCa who underwent RARP at 6 centers in Japan were included. Patients were categorized into 2 groups: those who underwent RARP alone (RARP-alone group) and those who underwent RARP following NHT (NHT group). The primary endpoint was biochemical recurrence-free survival (BRFS) after RARP.</div></div><div><h3>Results</h3><div>A total of 976 patients were analyzed, including 140 patients in each group after propensity score matching. At a median follow-up of 47 months, BCR was observed in 40.7% of patients in the RARP-alone group and 31.4% in the NHT group (<em>P</em> = .106). BRFS rates did not significantly differ between the 2 groups (<em>P</em> = .671). The RARP-alone group tended to have slightly longer operative times and more positive surgical margins than the NHT group.</div></div><div><h3>Conclusion</h3><div>This study suggests that NHT does not improve BRFS in patients with HR/VHR-PCa undergoing RARP. Further research is necessary to develop more effective neoadjuvant regimens for this patient population.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 3","pages":"Article 102346"},"PeriodicalIF":2.3,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143886458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World Study","authors":"Ghady Bou-Nehme Sawaya ,&nbsp;Simon Tanguay ,&nbsp;Lori A. Wood ,&nbsp;Christian Kollmannsberger ,&nbsp;Naveen S. Basappa ,&nbsp;Rahul Bansal ,&nbsp;Denis Soulières ,&nbsp;Antonio Finelli ,&nbsp;Daniel Y.C. Heng ,&nbsp;Vincent Castonguay ,&nbsp;Christina Canil ,&nbsp;Eric Winquist ,&nbsp;Jeffrey Graham ,&nbsp;Georg A. Bjarnason ,&nbsp;Bimal Bhindi ,&nbsp;Aly-Khan Lalani ,&nbsp;Frédéric Pouliot ,&nbsp;Rodney H. Breau ,&nbsp;Ramy Saleh ,&nbsp;Alice Dragomir","doi":"10.1016/j.clgc.2025.102342","DOIUrl":"10.1016/j.clgc.2025.102342","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the outcomes of metastatic renal cell carcinoma (mRCC) patients, with or without sarcomatoid features, who underwent cytoreductive nephrectomy (CN) before or after systemic therapies (ST).</div></div><div><h3>Methods</h3><div>Synchronous metastatic RCC patients of IMDC intermediate- and high-risk diagnosed between January 2011 to December 2022, treated with CN before or after ST, and with histological documentation of the presence or absence of sarcomatoid features in nephrectomy specimens were identified using the Canadian Kidney Cancer information system (CKCis). Patients were classified by treatment sequence received: (1) CN after ST (2) CN before ST. Inverse probability of treatment weighting using propensity scores was used to balance for covariates. Cox proportional hazards models were used to assess the impact of initial treatment received on overall survival (OS).</div></div><div><h3>Results</h3><div>Of 709 eligible patients, 105 were treated with CN after ST and 604 with CN before ST. 75% were male, and the majority (70%) received targeted therapies (TT) used alone. In nonsarcomatoid patients (80 CN after ST and 454 CN before ST), treatment with CN after ST was associated with an improvement in OS, that was not statistically significant, compared to CN before ST (median of 60 vs. 48 months, HR 0.84, 95% CI 0.64-1.11). In sarcomatoid patients (25 CN after ST and 150 CN before ST), CN after ST was also not associated with better survival (median of 24 vs. 36 months, HR 1.10, 95% CI 0.70-1.73).</div></div><div><h3>Conclusion</h3><div>In conclusion, this study demonstrated that, no matter the sarcomatoid status, there is no statistical difference between receiving CN after ST or CN before ST. The timing of CN could potentially be linked more so to clinical assessments than the knowledge of sarcomatoid status.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 3","pages":"Article 102342"},"PeriodicalIF":2.3,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}